Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.

McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H.

Arch Gen Psychiatry. 2002 Oct;59(10):921-8.

PMID:
12365879
2.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
3.

Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial.

Alvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL, Pérez-Iglesias R, Martínez-García O, Pérez-Pardal T, Ramírez-Bonilla ML, Crespo-Facorro B.

J Clin Psychiatry. 2006 Aug;67(8):1253-60.

PMID:
16965204
4.

Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis.

Yung AR, Phillips LJ, Nelson B, Francey SM, PanYuen H, Simmons MB, Ross ML, Kelly D, Baker K, Amminger GP, Berger G, Thompson AD, Thampi A, McGorry PD.

J Clin Psychiatry. 2011 Apr;72(4):430-40. doi: 10.4088/JCP.08m04979ora. Epub 2010 Oct 19.

PMID:
21034687
6.

Early intervention in patients at ultra high risk of psychosis: benefits and risks.

de Koning MB, Bloemen OJ, van Amelsvoort TA, Becker HE, Nieman DH, van der Gaag M, Linszen DH.

Acta Psychiatr Scand. 2009 Jun;119(6):426-42. doi: 10.1111/j.1600-0447.2009.01372.x. Epub 2009 Mar 10. Review.

PMID:
19392813
7.

Monitoring and care of young people at incipient risk of psychosis.

Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A.

Schizophr Bull. 1996;22(2):283-303. Review.

PMID:
8782287
8.

Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics.

Phillips LJ, Nelson B, Yuen HP, Francey SM, Simmons M, Stanford C, Ross M, Kelly D, Baker K, Conus P, Amminger P, Trumpler F, Yun Y, Lim M, McNab C, Yung AR, McGorry PD.

Aust N Z J Psychiatry. 2009 Sep;43(9):818-29. doi: 10.1080/00048670903107625.

PMID:
19670055
9.

Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis.

Takahashi T, Wood SJ, Yung AR, Soulsby B, McGorry PD, Suzuki M, Kawasaki Y, Phillips LJ, Velakoulis D, Pantelis C.

Arch Gen Psychiatry. 2009 Apr;66(4):366-76. doi: 10.1001/archgenpsychiatry.2009.12.

PMID:
19349306
10.

Programma 2000: celebrating 10 years of activity of an Italian pilot programme on early intervention in psychosis.

Cocchi A, Meneghelli A, Preti A.

Aust N Z J Psychiatry. 2008 Dec;42(12):1003-12. doi: 10.1080/00048670802512032.

PMID:
19016088
11.

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE.

Arch Gen Psychiatry. 2010 Feb;67(2):146-54. doi: 10.1001/archgenpsychiatry.2009.192.

PMID:
20124114
12.

Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial.

Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP.

Br J Psychiatry. 2004 Oct;185:291-7.

13.

Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial.

Bertelsen M, Jeppesen P, Petersen L, Thorup A, Øhlenschlaeger J, le Quach P, Christensen TØ, Krarup G, Jørgensen P, Nordentoft M.

Arch Gen Psychiatry. 2008 Jul;65(7):762-71. doi: 10.1001/archpsyc.65.7.762.

PMID:
18606949
14.

Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project.

Jackson HJ, McGorry PD, Killackey E, Bendall S, Allott K, Dudgeon P, Gleeson J, Johnson T, Harrigan S.

Psychol Med. 2008 May;38(5):725-35. Epub 2007 Nov 16.

PMID:
18005494
15.

Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.

McGorry PD, Nelson B, Phillips LJ, Yuen HP, Francey SM, Thampi A, Berger GE, Amminger GP, Simmons MB, Kelly D, Dip G, Thompson AD, Yung AR.

J Clin Psychiatry. 2013 Apr;74(4):349-56. doi: 10.4088/JCP.12m07785. Epub 2012 Nov 27.

PMID:
23218022
16.

Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.

Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ; German Study Group on First-Episode Schizophrenia.

J Clin Psychiatry. 2007 Nov;68(11):1763-74.

PMID:
18052570
17.

Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.

Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M, Kechavan M, Cooley S, DiBarry AL, Garrett A, Parepally H, Zoretich R.

Arch Gen Psychiatry. 2004 Sep;61(9):866-76.

PMID:
15351765
19.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
20.

A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication.

Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, O'Carroll M, Barnes TR.

Arch Gen Psychiatry. 2000 Feb;57(2):165-72.

PMID:
10665619

Supplemental Content

Support Center